Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration.
Open Access
- 15 June 1991
- journal article
- Published by Rockefeller University Press in The Journal of cell biology
- Vol. 113 (6) , 1439-1445
- https://doi.org/10.1083/jcb.113.6.1439
Abstract
Conditioned medium (CM) derived from co-cultures of bovine aortic endothelial cells (BAECs) and bovine smooth muscle cells (BSMCs) contains transforming growth factor-beta (TGF-beta) formed via a plasmin-dependent activation of latent TGF-beta (LTGF beta), which occurs in heterotypic but not in homotypic cultures (Sato, Y., and D. B. Rifkin. 1989. J. Cell Biol. 107: 1199-1205). The TGF-beta formed is able to block the migration of BSMCs or BAECs. We have found that the simultaneous addition to heterotypic culture medium of plasminogen and the atherogenic lipoprotein, lipoprotein (a) (Lp(a)), which contains plasminogen-like kringles, inhibits the activation of LTGF-beta in a dose-dependent manner. The inclusion of LDL in the culture medium did not show such an effect. Control experiments indicated that Lp(a) does not interfere with the basal level of cell migration, the activity of exogenous added TGF-beta, the release of LTGF-beta from cells, the activation of LTGF-beta either by plasmin or by transient acidification, or the activity of plasminogen activator. The addition of Lp(a) to the culture medium decreased the amount of plasmin found in BAECs/BSMCs cultures. Similar results were obtained using CM derived from cocultures of human umbilical vein endothelial cells and human foreskin fibroblasts. These results suggest that Lp(a) can inhibit the activation of LTGF-beta by competing with the binding of plasminogen to cell or matrix surfaces. Therefore, high plasma levels of Lp(a) might enhance smooth muscle cell migration by decreasing the levels of the migration inhibitor TGF-beta thus contributing to generation of the atheromatous lesions.Keywords
This publication has 37 references indexed in Scilit:
- Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor.Proceedings of the National Academy of Sciences, 1991
- Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture.The Journal of cell biology, 1989
- A potential basis for the thrombotic risks associated with lipoprotein(a)Nature, 1989
- Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.The Journal of cell biology, 1988
- Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a).Journal of Biological Chemistry, 1986
- Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.The Journal of Experimental Medicine, 1986
- The murine transforming growth factor-beta precursor.Journal of Biological Chemistry, 1986
- The Pathogenesis of Atherosclerosis — An UpdateNew England Journal of Medicine, 1986